Evidence map›Paper›PMID 30915205›Full record

ArticleHematology reports2019

Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery.

Gianluca Sottilotta, Francesca Luise, Vincenzo Oriana, Angela Piromalli, Rosa Santacroce, Alessandra Di Lelio

Open access · goldAbstract read
In one paragraph

Article in Hematology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Gianluca SottilottaUOSD Microcitemie - Centro Emofilia - Servizio Emostasi e Trombosi, Grande Ospedale Metropolitano Bianchi- Melacrino-Morelli, Reggio Calabria.
Francesca LuiseUOSD Microcitemie - Centro Emofilia - Servizio Emostasi e Trombosi, Grande Ospedale Metropolitano Bianchi- Melacrino-Morelli, Reggio Calabria.
Vincenzo OrianaUOSD Microcitemie - Centro Emofilia - Servizio Emostasi e Trombosi, Grande Ospedale Metropolitano Bianchi- Melacrino-Morelli, Reggio Calabria.
Angela PiromalliUOSD Microcitemie - Centro Emofilia - Servizio Emostasi e Trombosi, Grande Ospedale Metropolitano Bianchi- Melacrino-Morelli, Reggio Calabria.
Rosa SantacroceServizio di Genetica Medica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Foggia.
Alessandra Di LelioCenter for Outcomes Research and Clinical Epidemiology - CORESEARCH, Pescara, Italy.
Azienda ospedaliera "Bianchi-Melacrino-Morelli" · ITCenter for Outcomes Research and Clinical Epidemiology · ITOspedali Riuniti di Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite many articles regarding the antihemorrhagic treatment and prophylaxis, there is a lack of experience about how to best conduct major surgical procedures in patients with congenital factor XIII (FXIII) deficiency. Here we report a case of surgery (right inguinal hernia, complicated by heaviness and pain) performed in a patient with FXIII deficiency, receiving recombinant FXIII prophylaxis (Catridecacog 35 UI/kg every 28±2 days). Our experience shows that Catridecacog can be used safely and effectively not only for continued prophylaxis but also in surgery and adds to the very limited body of evidence currently available on surgery in this bleeding disorder.

Indexed as

congenital FXIII deficiencyRecombinant FXIIIsurgery

Identifiers

PMID30915205
PMCPMC6397991
OpenAlexW2918016166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.